PT - JOURNAL ARTICLE AU - Siwy, Justyna AU - Wendt, Ralph AU - Keller, Felix AU - Banasik, Miroslaw AU - Peters, Björn AU - Dudoignon, Emmanuel AU - Mebazaa, Alexandre AU - Gülmez, Dilara AU - Spasovski, Goce AU - Lazo, Mercedes Salgueira AU - Mischak, Harald AU - Hecking, Manfred AU - Beige, Joachim AU - , TI - Mortality risk in survivors of acute COVID-19 and the urinary proteome: Follow-up results from a multinational study that prospectively evaluated a proteomic urine test for early and accurate prognosis of critical course complications in patients with SARS-CoV-2 infection (CRIT-COV-U) AID - 10.1101/2024.06.26.24309460 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.26.24309460 4099 - http://medrxiv.org/content/early/2024/06/27/2024.06.26.24309460.short 4100 - http://medrxiv.org/content/early/2024/06/27/2024.06.26.24309460.full AB - Survival prospects following SARS-CoV-2 infection extend beyond the acute phase, influenced by various factors including age, health conditions, and infection severity. We investigated mortality risk among 651 post-acute COVID-19 patients, assessing the association between urinary peptides and future death. Data spanning until December 2023 were collected from six countries, comparing mortality trends with age- and sex-matched non-infected controls. A death prediction classifier was developed and validated using pre-existing urinary peptidomics datasets. Notably, 13.98% of post-COVID-19 patients succumbed during the follow-up, with mortality rates significantly higher than non-infected controls, particularly evident in younger individuals (<65 years). Urinary peptide analysis identified 201 peptides linked to mortality, integrated into a predictive classifier (DP201). Higher DP201 scores, alongside age and BMI, significantly predicted death. These findings underscore the utility of urinary peptides in prognosticating post-acute COVID-19 mortality, offering insights for targeted interventions.Competing Interest StatementH.M. the co-founder and co-owner of Mosaiques Diagnostics. J.S. is employed by Mosaiques-Diagnostics GmbH.Funding StatementThis project was supported by Federal Ministry of Health (BMG) via grant number 25323FSB114; by the German ministry for education and science (BMBF), via grant 01KU2309; by the Swedish governmental agency for innovation systems (Vinnova), via gran 2022-00542; by National Centre for Research and Development (Narodowe Centrum Badań i Rozwoju), via grant number: PerMed/V/162/UriCov/2023; by Austrian Science Fund (FWF) via Project number I 6464, Grant-DOI 10.55776/I6464; and by the French National Research Agency Agence Nationale de la Recherche (ANR), under the grant ANR-22-PERM-0014 and in part by Austrian Science Fund (FWF) via Project number I 6471, Grant-DOI 10.55776/I6471 under the frame of ERA PerMed.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the German-Saxonian Board of Physicians (Dresden, Germany; number EK-BR-70/23-1) and the Institutional Review Boards of the recruiting sites provided ethical approvalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available upon request from the corresponding author